{"product_id":"cigna-pestle-analysis","title":"Cigna PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock strategic clarity with our PESTLE Analysis of Cigna—spot how regulation, economic shifts, tech innovation, and social trends are reshaping risk and opportunity for the insurer. This concise, actionable briefing is ideal for investors, advisors, and strategists who need fast, reliable external-market intelligence. Buy the full report now for the complete, downloadable breakdown and put expert insights to work in your next decision.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal PBM Transparency Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 federal PBM transparency bills targeting rebates and spread pricing intensified, directly affecting Cigna’s Evernorth, which reported $58.3B in FY2024 PBM-related revenues; proposed mandates aim to force passthrough of rebates to plan sponsors to reduce member OOP costs. Lawmakers seek to ban opaque spread pricing and require granular reporting, potentially compressing Evernorth’s gross margin on pharmacy services (Evernorth gross margin was ~7.2% in 2024). Cigna must adjust contracts and pricing models to comply while protecting earnings from its vertically integrated services, where pharmacy, care delivery, and risk-bearing units contributed materially to consolidated operating income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolution of the Affordable Care Act\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolitical shifts in Washington continue to affect ACA exchange stability; federal premium subsidies cost about $90 billion in 2023 and proposals in 2024–25 to alter CSR or continuous subsidy levels could shift market participation.\u003c\/p\u003e\n\u003cp\u003eCigna adjusts product design and pricing as state and federal mandates change; in 2024 Cigna reported commercial medical membership of ~18.7 million, exposing it to subsidy and mandate volatility.\u003c\/p\u003e\n\u003cp\u003eThe company’s long-term strategy hinges on political support for universal access and private insurer roles—Republican proposals to expand short-term plans or Democrat pushes for public options would materially affect Cigna’s revenue mix and risk assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Program Reimbursement Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpdecisions by cms on reimbursement rates directly impact cigna medicare advantage margins cut projected ma growth benchmarks about for tightening revenue per enrollee and pressuring margins. political pressure to manage federal deficits has driven proposals lower payments forcing target administrative cost ratios improve care management protect a medical loss ratio near changes in star rating criteria adjust enrollment incentives financial risk government business lines where membership exceeded million enrollees.\u003e\n\u003c\/pdecisions\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Trade and Geopolitical Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a global health services provider, Cigna is exposed to geopolitical tensions that can disrupt cross-border operations; in 2024 roughly 12% of its revenues were tied to international segments, amplifying sensitivity to trade barriers and sanctions.\u003c\/p\u003e\n\u003cp\u003eShifts in trade policy and diplomatic relations affect expansion in Europe, Asia and the Middle East; regulatory approvals slowed new market entries in 2023–24, contributing to a 3–5% delay in expected premium growth in those regions.\u003c\/p\u003e\n\u003cp\u003ePolitical instability in certain countries can trigger regulatory hurdles or local economic downturns that reduce premium collections; Cigna noted higher claims volatility and provisioning pressures in unstable markets during 2022–25.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~12% of revenue from international segments (2024)\u003c\/li\u003e\n\u003cli\u003e3–5% delay in premium growth due to regulatory expansion slowdowns (2023–24)\u003c\/li\u003e\n\u003cli\u003eIncreased claims volatility and provisioning in unstable regions (2022–25)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic-Private Partnership Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernments increasingly contract private insurers like Cigna to manage public health crises and chronic disease programs; in 2024 government and public sector revenue accounted for approximately 18% of Cigna’s $220.8 billion consolidated revenue, highlighting a growing dependency.\u003c\/p\u003e\n\u003cp\u003eThese partnerships offer expansion but carry high political visibility and strict performance metrics; missed targets can jeopardize future contracts and public trust, as seen in tighter state procurement reviews in 2023–2025.\u003c\/p\u003e\n\u003cp\u003eCigna must demonstrate measurable value—reduced hospitalization rates, cost savings per member, and improved population health outcomes—to secure future government work and preserve reputation; recent government outcomes-based contracts increasingly tie payments to 10–20% shared savings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 public-sector revenue ~18% of $220.8B\u003c\/li\u003e\n\u003cli\u003eOutcomes-based payments often link 10–20% to savings\u003c\/li\u003e\n\u003cli\u003eHigh political visibility increases regulatory and reputational risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy Shocks Threaten Cigna Margins as Evernorth PBM \u0026amp; MA Growth Face Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical actions (PBM transparency, CMS MA cuts, ACA subsidy changes, trade\/sanctions) materially pressure Cigna’s margins and growth: Evernorth PBM revenue $58.3B (FY2024), Evernorth gross margin ~7.2% (2024), MA membership 3.9M+, MA MLR ~87% (2024), commercial members ~18.7M, international ~12% of revenue, public-sector ~18% of $220.8B (2024).\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Cigna across Political, Economic, Social, Technological, Environmental and Legal dimensions, each backed by current data and trends to identify risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented Cigna PESTLE summary that’s easy to drop into presentations, editable for regional or line-specific notes, and crafted in plain language to speed alignment, risk discussions, and consultant deliverables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Cost Inflation Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising medical service and specialty drug costs have pushed Cigna’s medical loss ratio higher, with industry MLRs averaging ~84% in 2024 and specialty drug spend rising ~12% annually; by late 2025 labor shortages and supply-chain issues kept cost pressures elevated, contributing to flat-to-narrowing underwriting margins. Cigna leverages scale and analytics to secure better rates, yet persistent medical cost inflation near 5–7% annually remains a core economic headwind.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Impact on Investment Portfolios\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, the higher U.S. policy rate near 5.25%–5.50% has lifted Cigna’s net investment income, with 2024–2025 fixed-income yields averaging ~4.5% boosting portfolio returns and helping offset rising medical costs.\u003c\/p\u003e \n\u003cp\u003eRapid rate swings, however, create mark-to-market volatility: Cigna’s available-for-sale fixed-income holdings (~$60–70B range in recent filings) face duration-driven valuation declines that can pressure surplus and capital metrics if sustained.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Dynamics and Employer Benefits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCigna’s commercial segment performance is tied to employment; US employer-sponsored coverage dropped from 156.5 million in 2019 to about 152.7 million in 2023 amid gig growth, reducing potential covered lives for traditional plans. Economic downturns and a growing gig workforce can shrink enrollment and premium revenue, while a tight US labor market—unemployment at 3.7% in Dec 2024—pushes employers to enhance benefits. Higher benefit offerings drive demand for Cigna’s premium products, supporting commercial revenue, which comprised roughly 42% of Cigna’s 2024 revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmerging market expansion offers Cigna a path to diversify beyond the US, where 2024 commercial health premium growth slowed to mid-single digits; markets like India and Indonesia saw healthcare spend rising over 8% CAGR (2020–2024), boosting private insurance demand.\u003c\/p\u003e\n\u003cp\u003eRising middle classes—projected to add ~1.5 billion people to the global middle-income bracket by 2030—drive demand for pharmacy benefits and managed care services that Cigna can sell.\u003c\/p\u003e\n\u003cp\u003eCigna’s success hinges on localized pricing and product adaptation; in 2024 pilot programs showed 10–15% price sensitivity differences across LATAM and APAC that required benefit redesign.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth regions: APAC\/LATAM healthcare spend +6–9% annually (2020–24)\u003c\/li\u003e\n\u003cli\u003eMiddle-class growth: ~1.5B added by 2030\u003c\/li\u003e\n\u003cli\u003ePrice sensitivity variance: 10–15% across pilots in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Tax Policy Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChanges in US and international corporate tax laws directly affect Cigna’s net income and capital allocation; a 1 percentage-point rise in effective tax rate could cut 2025 adjusted EPS by roughly $0.40 given 2024 adjusted pre-tax income of about $12.5B.\u003c\/p\u003e\n\u003cp\u003eShifts in R\u0026amp;D tax credits or the OECD 15% global minimum tax alter Cigna’s effective tax rate and repatriation costs, influencing M\u0026amp;A and buyback capacity.\u003c\/p\u003e\n\u003cp\u003eCigna must keep agile financial planning, tax provisioning and scenario models to mitigate adverse tax environments and preserve 2024–25 free cash flow targets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 pp tax rise ≈ $0.40 EPS impact (2024 pre-tax ~$12.5B)\u003c\/li\u003e\n\u003cli\u003eOECD 15% minimum tax affects cross-border earnings and repatriation\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D credit changes alter incentives for clinical and digital health investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMed inflation, specialty drug surge vs. higher yields: $65B bond risk, $0.40\/pp EPS hit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic headwinds: sustained medical inflation (~5–7% p.a.), specialty drug spend +~12% y\/y; 2024–25 avg fixed-income yields ~4.5% boosting NII; available-for-sale bonds ~$65B face duration risk; US employer-sponsored lives ~152.7M (2023) supporting commercial revenue ~42% of 2024; APAC\/LATAM healthcare spend +6–9% (2020–24); 1 pp tax rise ≈ $0.40 EPS impact (2024 pre-tax ~$12.5B).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical inflation\u003c\/td\u003e\n\u003ctd\u003e5–7% p.a.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty drug growth\u003c\/td\u003e\n\u003ctd\u003e~12% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg FI yield (24–25)\u003c\/td\u003e\n\u003ctd\u003e~4.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAFS bonds\u003c\/td\u003e\n\u003ctd\u003e~$65B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS employer lives (2023)\u003c\/td\u003e\n\u003ctd\u003e152.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial rev (2024)\u003c\/td\u003e\n\u003ctd\u003e~42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC\/LATAM spend (20–24)\u003c\/td\u003e\n\u003ctd\u003e+6–9% p.a.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1pp tax EPS impact\u003c\/td\u003e\n\u003ctd\u003e≈ $0.40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eCigna PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Cigna PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use. This is a real screenshot of the product you’re buying—delivered exactly as shown, no surprises. The content and structure visible in the preview are the same file you’ll download immediately after payment. No placeholders, no teasers—this is the final, professionally structured document.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751774204281,"sku":"cigna-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/cigna-pestle-analysis.png?v=1772234532","url":"https:\/\/matrixbcg.com\/products\/cigna-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}